ArticleTranslational cancer research2025
Identification of the MEX3 family as potential biomarkers of hepatocellular carcinoma based on bioinformatics and experiments.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MEX3B aggravates osteoarthritis progression by post-transcriptionally activating TLR4-NF-κB signaling axis.Journal of orthopaedic surgery and research · 2026Article
- The molecular sub-type and the development and validation of a prognosis prediction model based on endocytosis-related genes for hepatocellular carcinoma.Journal of gastrointestinal oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Members of the MEX3 RNA-binding protein family have been widely recognized as critical in the development and progression of cancer. However, the specific role of MEX3 in liver hepatocellular carcinoma (LIHC) remains largely unexplored. This study aims to exploring the potential functions and mechanisms of MEX3 family genes in LIHC. Methods: To address this gap, we performed a comprehensive bioinformatics analysis using various tools and databases, including the The Cancer Genome Atlas (TCGA) dataset, R software, Kaplan-Meier Plotter, cBioPortal, LinkedOmics, Metascape, TIMER, receiver operating characteristic (ROC) curve, and nomogram. Furthermore, the protein levels of MEX3 family were assessed by Western blot and the Human Protein Atlas. Results: Our analyses revealed that MEX3 family genes were significantly overexpressed in multiple types of tumor tissues, particularly in LIHC. Specifically, MEX3A was highly expressed in Asian populations, while MEX3B/C/D showed increased expression in tumors of higher grades and advanced clinical stages. High expression of MEX3A correlated with poor survival outcomes; MEX3C/D showed partial associations with poor survival, whereas MEX3B indicated a favorable trend. Mutations in the Conclusions: Our findings suggest that the MEX3 family is associated with the prognosis of hepatocellular carcinoma patients and contributes to disease progression by modulating the cell cycle and protein post-transcriptional modifications. Furthermore, this family is related to the tumor microenvironment, particularly in hypoxia and immune responses, which holds significant value for predicting liver cancer outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.